Analgesics and Anti-inflammatory Drugs Practice Questions

Q: An otherwise healthy 15-month-old boy is brought to the emergency department by his mother 1 hour after having a single episode of generalized tonic-clonic seizure, which stopped spontaneously after 1 minute. He was sleepy initially but is now awake and alert. His mother reports that he has had a fever and runny nose for the past 3 days. His temperature is 40.1°C (104.2°F). Physical examination shows no abnormalities. Analysis of his cerebrospinal fluid shows 3 cells/mm3, a glucose concentration of 68 mg/dL, and a protein concentration of 35 mg/dL. Administration of a drug that acts through which of the following mechanisms of action is most appropriate in this patient?

Decreasing production of prostaglandin E2. Decreasing production of prostaglandin E2 - This patient presents with a **febrile seizure**, characterized by a seizure in the setting of fever without evidence of intracranial infection or metabolic derangement [1]. He has no neurological deficits, and the CSF analysis rules out **meningitis** or **encephalitis**. - The most appropriate treatment for preventing recurrence and managing the fever is an **antipyretic** (e.g., ibuprofen, acetaminophen), which acts by inhibiting **prostaglandin E2** synthesis to reduce the febrile response. *Blocking voltage-gated Na+ channels* - This mechanism is characteristic of several **antiepileptic drugs** (e.g., phenytoin, carbamazepine, lamotrigine), which are typically used for **focal** and **generalized tonic-clonic seizures** [2]. - However, for a simple febrile seizure, chronic antiepileptic therapy is not recommended due to potential side effects and lack of proven benefit in preventing future febrile seizures or epilepsy. *Blocking T-type Ca2+ channels* - This is the primary mechanism of action for **ethosuximide**, an antiepileptic drug specifically used to treat **absence seizures**. - The patient had a generalized tonic-clonic seizure, not an absence seizure, and the context is a febrile event, making this mechanism irrelevant. *Increasing duration of Cl− channel opening* - This is the mechanism of action for **benzodiazepines** (e.g., lorazepam, diazepam), which are used to terminate **active seizures** by enhancing GABAergic inhibition [3]. - The patient's seizure has already stopped spontaneously, and he is awake and alert, so immediate administration of a benzodiazepine is not indicated for acute seizure termination.

Q: The shortest acting opioid is:-

Remifentanil. ***Remifentanil*** - **Remifentanil** is an **ultra-short-acting opioid** due to its unique metabolism by **non-specific plasma and tissue esterases**. - Its rapid metabolism results in a very short context-sensitive half-time, meaning its effects **terminate quickly** regardless of infusion duration. *Alfentanil* - **Alfentanil** is a **short-acting opioid** but its duration of action is longer than remifentanil. - It is eliminated primarily by **hepatic metabolism**, which is slower than esterase-based metabolism. *Fentanyl* - **Fentanyl** is a **potent synthetic opioid** with an intermediate duration of action. - Its elimination is dependent on **hepatic metabolism**, and it has a longer context-sensitive half-time compared to remifentanil. *Sufentanil* - **Sufentanil** is a **very potent opioid** with a longer duration of action than fentanyl and alfentanil. - Its metabolism is hepatic, leading to a **longer elimination half-life** and thus a more prolonged effect.

Q: Mechanism of action of allopurinol is

Xanthine oxidase inhibition. ***Xanthine oxidase inhibition*** - **Allopurinol** acts as a **structural analog of hypoxanthine** and competitively inhibits the enzyme **xanthine oxidase**. - By inhibiting **xanthine oxidase**, allopurinol prevents the conversion of hypoxanthine to xanthine and then to uric acid, thereby **decreasing uric acid production**. *Recombinant uricase* - **Recombinant uricase** (e.g., rasburicase, pegloticase) is an enzyme that catalyzes the breakdown of existing uric acid into allantoin, a more soluble compound. - This mechanism is distinct from allopurinol, which **prevents uric acid formation**. *Decrease chemotaxis* - Medications that **decrease chemotaxis**, such as **colchicine**, work by interfering with the migration of neutrophils to sites of inflammation, which is useful in acute gout flares. - This is an **anti-inflammatory mechanism**, not related to uric acid synthesis or excretion. *Increase uric acid excretion* - Drugs that **increase uric acid excretion** are known as **uricosurics** (e.g., probenecid, lesinurad). - These agents act on the renal tubules to **inhibit uric acid reabsorption**, thus promoting its elimination from the body.

Q: Allopurinol inhibits which enzyme?

Xanthine oxidase. ***Xanthine oxidase*** - Allopurinol is a **purine analog** that acts as a **competitive inhibitor** of the enzyme **xanthine oxidase**. - By inhibiting xanthine oxidase, allopurinol prevents the conversion of **hypoxanthine to xanthine** and subsequently to **uric acid**, thereby lowering serum uric acid levels. *Lysyl oxidase* - **Lysyl oxidase** is an enzyme involved in the **cross-linking of collagen and elastin**, crucial for the stability of connective tissues. - Its inhibition would not directly affect **uric acid metabolism** or be a mechanism of allopurinol's action. *Cyclooxygenase* - **Cyclooxygenase (COX)** is a key enzyme in the synthesis of **prostaglandins and thromboxanes** from arachidonic acid, mediating inflammation and pain. - **NSAIDs** are inhibitors of cyclooxygenase, not allopurinol. *Kinase* - **Kinases** are a broad class of enzymes that **catalyze the transfer of phosphate groups** from high-energy molecules (like ATP) to specific substrates. - While essential for many cellular processes, kinases are not the specific target of **allopurinol** in uric acid reduction.

Q: All of the following can be routes of opioid administration except:

Intradermal. ***Intradermal*** - **Intradermal administration** involves injecting medication into the dermis, the layer between the epidermis and the subcutaneous tissue, and is typically used for **allergy testing** or **tuberculosis screening (PPD test)**, not for systemic opioid delivery. - The **slow absorption rate** and **small volume capacity** of the dermal layer make it unsuitable for achieving therapeutic opioid concentrations quickly or effectively. *Intramuscular* - **Intramuscular (IM)** injection allows for **rapid absorption** of opioids into the bloodstream from the muscle tissue. - It is a common route for administering **analgesics**, including opioids, especially in settings where oral administration is not feasible or faster onset is desired. *Oral* - **Oral (PO) administration** is a common and convenient route for many opioid formulations, allowing for **systemic absorption** through the gastrointestinal tract. - Opioids like **oxycodone**, **hydrocodone**, and **morphine** are often prescribed as oral tablets or solutions for pain management. *Intravenous* - **Intravenous (IV) administration** provides the **fastest onset of action** for opioids, as the medication is directly introduced into the bloodstream. - This route is critically important in **acute pain management**, surgical settings, and emergency situations where immediate pain relief is necessary.

Q: Which of the following increases uric acid excretion?

Probenecid. **Probenecid** - **Probenecid** is a **uricosuric agent** that increases renal excretion of uric acid by inhibiting its reabsorption in the proximal tubule. - It is used in the treatment of **chronic gout** to lower serum uric acid levels. *Allopurinol* - **Allopurinol** works by inhibiting **xanthine oxidase**, an enzyme responsible for uric acid synthesis, thereby reducing its production. - It does not increase uric acid excretion but rather decreases its formation, making it suitable for **overproducers** of uric acid. *Aspirin* - **Low-dose aspirin** can actually *decrease* uric acid excretion by interfering with tubular secretion of uric acid. - **High-dose aspirin** has a uricosuric effect, but it is not typically used for gout due to side effects and more effective alternatives. *Colchicine* - **Colchicine** is an **anti-inflammatory agent** used to treat acute gout flares by inhibiting neutrophil chemotaxis and activation. - It does **not affect uric acid synthesis or excretion** directly, but rather mitigates the inflammatory response to uric acid crystals.

Q: Capsaicin acts on ______

Vanilloid receptor. ***Vanilloid receptor*** - Capsaicin is the active component of chili peppers and exerts its effects primarily through activation of the **transient receptor potential vanilloid 1 (TRPV1) receptor**, also known as the vanilloid receptor. - Activation of **TRPV1** by capsaicin leads to an influx of **calcium ions**, causing depolarization and firing of nociceptive neurons, which is perceived as burning pain. *Capsaicoid receptor* - This term is **not a recognized scientific receptor name** for capsaicin's primary target. - It might be a colloquial or misnomer derived from the mechanism of action of capsaicin. *AMPA receptor* - **AMPA receptors** are **ionotropic glutamate receptors** that mediate fast synaptic transmission in the central nervous system. - They are primarily involved in learning, memory, and synaptic plasticity, not directly activated by capsaicin. *NMDA receptor* - **NMDA receptors** are another type of **ionotropic glutamate receptor** that plays a crucial role in synaptic plasticity and learning. - Although also involved in pain processing, they are distinct from the **TRPV1 receptor** and are not directly activated by capsaicin.

Q: Drug used in osteoarthritis

Glucosamine. ***Correct: Glucosamine*** - **Glucosamine** is a common dietary supplement often used to treat **osteoarthritis (OA)** symptoms, believed to help rebuild cartilage. - While its efficacy is debated, many patients report symptom relief, and it is considered relatively safe for OA management. *Incorrect: Sulfasalazine* - **Sulfasalazine** is a disease-modifying antirheumatic drug (DMARD) primarily used to treat inflammatory conditions like **rheumatoid arthritis (RA)** and **inflammatory bowel disease (IBD)**. - It is not indicated for the treatment of **osteoarthritis**, which is a degenerative joint disease rather than an inflammatory one. *Incorrect: Methotrexate* - **Methotrexate** is a powerful immunosuppressant and DMARD used in conditions such as **rheumatoid arthritis (RA)**, **psoriasis**, and some cancers. - Its mechanism of action targets inflammation and immune responses, which are not the primary drivers of **osteoarthritis**, making it an inappropriate treatment. *Incorrect: All of the options* - This option is incorrect because neither **Sulfasalazine** nor **Methotrexate** are primary treatments for osteoarthritis. - Only glucosamine is commonly associated with osteoarthritis treatment among the choices provided.

Q: Prolonged allopurinol therapy in a patient with gout is NOT indicated for:

Acute gouty arthritis. ***Acute gouty arthritis*** - Allopurinol is a **urate-lowering therapy** used for the chronic management of **hyperuricemia** and prevention of future gout flares, but it is not indicated for the acute treatment of a gouty arthritis attack [1]. - Starting allopurinol during an acute flare can sometimes **exacerbate the attack** by causing rapid fluctuations in serum uric acid levels. *Tophi* - Tophi are **deposits of urate crystals** in soft tissues, a clear indication of advanced gout and chronic hyperuricemia [2]. - Allopurinol therapy is indicated to reduce uric acid levels to dissolve existing tophi and prevent new ones from forming. *Urate nephropathy* - **Urate nephropathy** (or uric acid nephrolithiasis) occurs due to the precipitation of uric acid crystals in the kidneys, leading to kidney damage and stones [1], [2]. - Allopurinol reduces uric acid production, thereby preventing crystal formation and is therefore indicated. *Evidence of bone/joint damage* - Chronic gout can lead to **erosions and structural damage** in bones and joints due to persistent urate crystal deposition and inflammatory responses [2]. - Long-term allopurinol therapy is crucial to lower uric acid levels and prevent further damage, as well as to promote the regression of existing urate deposits.

Q: NSAID used commonly for topical ocular use is

Ketorolac. ***Ketorolac*** - **Ketorolac tromethamine** is a potent NSAID commonly formulated as an ophthalmic solution for topical ocular use. - It is effective in reducing **post-operative inflammation** and pain following ocular surgery, such as cataract extraction. *Ibuprofen* - While ibuprofen is a widely used oral NSAID, it is **not commonly available** or prescribed as a topical ophthalmic preparation. - Its primary use is for systemic pain and inflammation relief. *Acetaminophen* - **Acetaminophen (paracetamol)** is an analgesic and antipyretic but is classified as a non-opioid analgesic and generally **not considered an NSAID** due to its minimal anti-inflammatory properties through COX inhibition. - It is not used for topical ocular administration to treat inflammation. *Aceclofenac* - Aceclofenac is an NSAID used systemically for inflammatory conditions, but it is **not commonly formulated** or used as a topical ocular agent. - **Diclofenac**, a related NSAID, is available as an ophthalmic solution, but not aceclofenac.

Question 1

An otherwise healthy 15-month-old boy is brought to the emergency department by his mother 1 hour after having a single episode of generalized tonic-clonic seizure, which stopped spontaneously after 1 minute. He was sleepy initially but is now awake and alert. His mother reports that he has had a fever and runny nose for the past 3 days. His temperature is 40.1°C (104.2°F). Physical examination shows no abnormalities. Analysis of his cerebrospinal fluid shows 3 cells/mm3, a glucose concentration of 68 mg/dL, and a protein concentration of 35 mg/dL. Administration of a drug that acts through which of the following mechanisms of action is most appropriate in this patient?

Accepted Answer

Decreasing production of prostaglandin E2

Answer

Blocking voltage-gated Na+ channels

Answer

Blocking T-type Ca2+ channels

Answer

Increasing duration of Cl− channel opening

Question 2

The shortest acting opioid is:-

Accepted Answer

Remifentanil

Answer

Fentanyl

Answer

Alfentanil

Answer

Sufentanil

Question 3

Mechanism of action of allopurinol is

Accepted Answer

Xanthine oxidase inhibition

Answer

Recombinant uricase

Answer

Decrease chemotaxis

Answer

Increase uric acid excretion

Question 4

Allopurinol inhibits which enzyme?

Accepted Answer

Xanthine oxidase

Answer

Lysyl oxidase

Answer

Cyclooxygenase

Answer

Kinase

Question 5

All of the following can be routes of opioid administration except:

Accepted Answer

Intradermal

Answer

Intramuscular

Answer

Oral

Answer

Intravenous

Question 6

Which of the following increases uric acid excretion?

Accepted Answer

Probenecid

Answer

Allopurinol

Answer

Aspirin

Answer

Colchicine

Question 7

Capsaicin acts on ______

Accepted Answer

Vanilloid receptor

Answer

Capsaicoid receptor

Answer

AMPA receptor

Answer

NMDA receptor

Question 8

Drug used in osteoarthritis

Accepted Answer

Glucosamine

Answer

Sulfasalazine

Answer

All of the options

Answer

Methotrexate

Question 9

Prolonged allopurinol therapy in a patient with gout is NOT indicated for:

Accepted Answer

Acute gouty arthritis

Answer

Tophi

Answer

Urate nephropathy

Answer

Evidence of bone/joint damage

Question 10

NSAID used commonly for topical ocular use is

Accepted Answer

Ketorolac

Answer

Ibuprofen

Answer

Acetaminophen

Answer

Aceclofenac

Analgesics and Anti-inflammatory Drugs — MCQs

Analgesics and Anti-inflammatory Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?